Does VEMURAFENIB Cause Second primary malignancy? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Second primary malignancy have been filed in association with VEMURAFENIB (ZELBORAF). This represents 0.1% of all adverse event reports for VEMURAFENIB.
7
Reports of Second primary malignancy with VEMURAFENIB
0.1%
of all VEMURAFENIB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Second primary malignancy From VEMURAFENIB?
Of the 7 reports, 2 (28.6%) required hospitalization, and 1 (14.3%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VEMURAFENIB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does VEMURAFENIB Cause?
Rash (1,202)
Arthralgia (783)
Off label use (782)
Fatigue (773)
Diarrhoea (655)
Nausea (601)
Pyrexia (569)
Death (505)
Alopecia (445)
Decreased appetite (383)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which VEMURAFENIB Alternatives Have Lower Second primary malignancy Risk?
VEMURAFENIB vs VENETOCLAX
VEMURAFENIB vs VENLAFAXINE
VEMURAFENIB vs VENTAVIS
VEMURAFENIB vs VENTOLIN
VEMURAFENIB vs VENTOLIN HFA